Table 2:

Changes in clinical outcomes

	Baseline	3-mos	6-mos	9-mos	12-mos	P value
Sweat chloride (ALL) (mmol/L)	99.0 ±18.5	48.7 ±19.2	---	---	---	<0.0001
Sweat chloride (no prior modulator) (mmol/L)	103.0 ±18.8	54.0 ±20.7	---	---	---	<0.0001
Sweat chloride (prior modulator) (mmol/L)	94.9 ±17.6	43.3 ±16.2	---	---	---	<0.0001
FEV1 (ALL)	63.8 ±24.7	73.0 ±25.8	78.7 ±22.8	75.3 ±25.4	74.7 ±25.6	0.003
FEV1 (no prior modulator)	57.4 ±26.9	67.9 ±28.6	71.3 ±28.1	71.1 ±27.9	68.7 ±27.9	0.03
FEV1 (prior modulator)	70.3 ±22.9	79.4 ±22.3	87.8 ±12.3	77.7 ±24.5	81.0 ±21.6	0.001
BMI (ALL)	22.6 ± 4.5	23.5 ± 4.3	23.6 ± 4.1	23.3 ± 3.4	23.7 ± 4.1	<0.0001
BMI (no prior modulator)	21.4 ±4.9	22.7 ±5.0	22.8 ±5.8	22.4 ±4.3	22.9 ±4.1	0.003
BMI (prior modulator)	23.3 ±3.3	24.1 ±3.2	24.4 ±2.9	23.8 ±2.6	24.2 ±3.2	0.003
Hospitalizations (All)	0.9 ± 1.4	---	---	---	0.02 ± 0.1	<0.0001
Hospitalizations (no prior modulator)	1.0 ± 1.1	---	---	---	0.04 ± 0.2	<0.0001
Hospitalizations (prior modulator)	0.7 ± 1.7	---	---	---	0.0 ± 0.0	<0.0001
Antibiotic courses (All)	2.4 ± 2.3	---	---	---	0.5 ± 0.7	<0.0001
Antibiotics (no prior modulator)	3.1 ± 2.1	---	---	---	0.6 ± 0.8	<0.0001
Antibiotics (prior modulator)	1.8 ± 2.4	---	---	---	0.3 ± 0.5	<0.0001
P. aeruginosa	45.1%	---	---	---	21.6%
MRSA	33.3%	---	---	---	15.7%
MSSA	35.3%	---	---	---	31.4%
BCC	3.9%	---	---	---	0%
Achromobacter	9.8%	---	---	---	2%
Stenotrophomonas	5.9%	---	---	---	4%
Normal resp flora	3.9%	---	---	---	29.4%

BCC- Burkholderia cepacia complex

P values determined by paired t-test for sweat chloride, hospitalizations and antibiotic courses and linear mixed effects model with post-hoc Sidak comparison for FEV₁ and BMI